A randomized, open-label, single-dose, 4-period crossover, comparative bioavailability study of 3 sustained-release formulations and an immediate-release formulation of vabicaserin (SCA-136) in healthy subjects
Latest Information Update: 24 Jan 2008
At a glance
- Drugs Vabicaserin (Primary)
- Indications Schizophrenia
- Focus Pharmacokinetics
- Sponsors Wyeth
- 19 Oct 2007 New trial record.